These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22440918)

  • 21. The race for interferon-free HCV therapies: a snapshot by the spring of 2012.
    De Clercq E
    Rev Med Virol; 2012 Nov; 22(6):392-411. PubMed ID: 22936636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
    Gane EJ; Roberts SK; Stedman CA; Angus PW; Ritchie B; Elston R; Ipe D; Morcos PN; Baher L; Najera I; Chu T; Lopatin U; Berrey MM; Bradford W; Laughlin M; Shulman NS; Smith PF
    Lancet; 2010 Oct; 376(9751):1467-75. PubMed ID: 20951424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C therapy with HCV NS5B polymerase inhibitors.
    Soriano V; Vispo E; de Mendoza C; Labarga P; Fernandez-Montero JV; Poveda E; Treviño A; Barreiro P
    Expert Opin Pharmacother; 2013 Jun; 14(9):1161-70. PubMed ID: 23621117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C.
    Crabbé R; Vuagniaux G; Dumont JM; Nicolas-Métral V; Marfurt J; Novaroli L
    Expert Opin Investig Drugs; 2009 Feb; 18(2):211-20. PubMed ID: 19236267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-hepatitis C virus drugs in development.
    Schaefer EA; Chung RT
    Gastroenterology; 2012 May; 142(6):1340-1350.e1. PubMed ID: 22537441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
    Watashi K
    Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophilin inhibitors.
    Gallay PA
    Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
    Chu TW; Kulkarni R; Gane EJ; Roberts SK; Stedman C; Angus PW; Ritchie B; Lu XY; Ipe D; Lopatin U; Germer S; Iglesias VA; Elston R; Smith PF; Shulman NS
    Gastroenterology; 2012 Apr; 142(4):790-5. PubMed ID: 22248659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.
    Quarato G; D'Aprile A; Gavillet B; Vuagniaux G; Moradpour D; Capitanio N; Piccoli C
    Hepatology; 2012 May; 55(5):1333-43. PubMed ID: 22135208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of Action of the Host-Targeting Agent Cyclosporin A and Direct-Acting Antiviral Agents against Hepatitis C Virus.
    Liu D; Ndongwe TP; Ji J; Huber AD; Michailidis E; Rice CM; Ralston R; Tedbury PR; Sarafianos SG
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.
    Lewis H; Cunningham M; Foster G
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):471-85. PubMed ID: 23199506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
    Ottosen S; Parsley TB; Yang L; Zeh K; van Doorn LJ; van der Veer E; Raney AK; Hodges MR; Patick AK
    Antimicrob Agents Chemother; 2015 Jan; 59(1):599-608. PubMed ID: 25385103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C therapy in non-genotype 1 patients: the near future.
    Wartelle-Bladou C; Le Folgoc G; Bourlière M; Lecomte L
    J Viral Hepat; 2012 Aug; 19(8):525-36. PubMed ID: 22762136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current progress in the treatment of chronic hepatitis C.
    Alexopoulou A; Papatheodoridis GV
    World J Gastroenterol; 2012 Nov; 18(42):6060-9. PubMed ID: 23155334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
    Guedj J; Dahari H; Shudo E; Smith P; Perelson AS
    Hepatology; 2012 Apr; 55(4):1030-7. PubMed ID: 22095398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antiviral therapies in the management of HCV infection.
    Farnik H; Zeuzem S
    Antivir Ther; 2012; 17(5):771-83. PubMed ID: 22626842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.